Topics

Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke

2019-10-21 12:45:31 | BioPortfolio

Summary

Following stroke, a recovery process is promptly initiated, which leads to a partial rehabilitation. However, a number of disabling residual symptoms may persist for years and include mental fatigue, depression, cognitive deficits, neurological problems and more. In the lack of an effective treatment these symptoms will lead to major consequences for the individual and the surrounding society. OSU6162 has in earlier clinical studies of stroke patients shown evidence of a favorable effect on residual symptoms, especially mental fatigue, together with a mild side effect profile.

In this phase II, randomized, placebo-controlled, two-armed study, a 16 week OSU6162 treatment will be compared to an equally long placebo treatment in patients with residual symptoms following stroke.

Description

Main objectives of this study are to evaluate the efficacy and safety of OSU6162 compared to placebo with respect to treatment response in post stroke patients.

Endpoints:

Primary endpoint is Clinical Global Impression of Change (CGI-C) after 16 weeks of treatment.

Secondary endpoints are:

CGI-C score after 4, 8 and 12 weeks of treatment. FAI; MFS; FSS; BDI; SF-36 scores after 4, 8, 12 and 16 weeks of treatment. Correlation between plasma concentration of OSU6162 and therapeutic response after 4 and 16 weeks of treatment.

Safety variables: AE/SAE, physical and neurological examinations, vital signs (blood pressure and puls) and laboratory test.

Study Design:

The treatment period is 16 weeks, during which all patients will make 7 study visits and have 4 telephone interviews.

Study visits include:

Visit 1: screening at week -2, Days -14 to -5 Visit 2: baseline at week 0 Visit 4: week 4 ± 3 days Visit 6: week 8 ± 3 days Visit 8: week 12 ± 3 days Visit 10: week 16 ± 3 days Visit 11: follow up at week 20 ± 7 days

Randomization and start of treatment with OSU6162 or placebo at baseline, visit 2, week 0. Study medication administered during all study visits from baseline at visit 2 to visit 8 at week 12.

Physical and neurological examinations, vital signs and weight recording during all study visits.

ECG recorded during visits 1 (week -2) and 10 (week 16). Blood (and urine) sampling for safety labs during visits 1 (week -2), visit 4 (week 4), visit 10 (week 16). Pregnancy test at visit 1 and 10.

Blood sampling for analysis of plasma OSU6162 concentration at visit 4 and 10.

Primary outcome measures and secondary outcome self-assessment tests performed during all study visits.

Telephone interviews at visit: 3 (week 2 ± 3 days), 5 (week 6 ± 3 days), 7 (week 10 ± 3 days) and 9 (week 14 ± 3 days.

Concomitant medication, adverse events and drug compliance are recorded during all visits and telephone interviews.

Dosing:

All patients in the OSU6162 group start with a dose of 15 mg BID. The dose is increased to a maximum of 30 mg BID after 4 weeks of treatment. Intermediate doses are allowed and the final dose is individually flexible, depending on the therapeutic response and presence of AE. In the placebo group patients receive tablets with identical appearance to active treatment tablets (OSU6162 15 mg), administered according to the same dosing regime as active treatment.

Data analysis and statistics:

Efficacy analyses will be based on Mixed Models for Repeated Measures (MMRM) analyses. The MMRM analyses use all the longitudinal observations at each post-baseline visit for the study period of interest. Significance tests will be based on estimated population marginal means and Type III test of fixed effects, using a two-sided test with the significance level of 0.05. Differences in distributions of categorical variables will be tested using the Chi-square test or Fisher's exact test.

Due to the large number of variables engendered, multivariate statistical evaluations will be performed as a complement to the above-mentioned statistical methods.

Before unblinding of the study data, a separate Statistical Analysis Plan (SAP) will be prepared.

Patient and data safety:

This study is conducted in accordance with the study protocol, the Declaration of Helsinki, ICH E6 GCP, the European Clinical Trials Directive 2001/20/EC and applicable local laws and regulations.

The Investigator is responsible for ensuring the accuracy, completeness, legibility and timeliness of the data recorded in the CRFs. Data recorded in the CRF that are derived from source documents should be consistent with the source documents or the discrepancies should be explained. Signed sections of CRFs are monitored and collected on a regular basis.

An individual secrecy agreement is established for all Sponsor, site personnel, independent auditors, and representatives from Competent Authorities that will have access to the information in the medical records for the participating patients.

Study Design

Conditions

Stroke Sequelae

Intervention

OSU 6162, Placebo oral tablet

Location

Gottfries Clinic AB
Gothenburg
Sweden
SE-43137

Status

Active, not recruiting

Source

A Carlsson Research AB

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-21T12:45:31-0400

Clinical Trials [4708 Associated Clinical Trials listed on BioPortfolio]

Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage

Many people who have undergone subarachnoid hemorrhage from an aneurysm (an artery of a vein in the brain) struggle with a pronounced fatigue as well as a number of other sequelae such as ...

Post-stroke Pathway: Analysis and Link With One Year Sequelae in a French Cohort of Stroke Patients

The link between post-stroke pathways and patient sequelae have not yet been clearly defined. The main purpose is to identify the post-stroke life pathways components associated with sequa...

A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927

The purpose of this trial was to evaluate the safety and tolerability of SPM 927 when given as iv infusions compared with oral administration of the same dose strengths in subjects who wer...

Imatinib in Acute Ischaemic Stroke

A clinical trial comparing treatment with Imatinib to placebo when administered within 8 hours of stroke onset for 6 days, in addition to conventional stroke treatment after acute ischaemi...

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due t...

PubMed Articles [7176 Associated PubMed Articles listed on BioPortfolio]

Post-stroke pathway analysis and link with one year sequelae in a French cohort of stroke patients: the PAPASePA protocol study.

Stroke is a health problem with serious consequences, both in terms of mortality, and after-effects affecting patient quality of life. Stroke requires both urgent and chronic management involving the ...

The association between oral bacteria, the cough reflex and pneumonia in patients with acute stroke and suspected dysphagia.

To establish how oral bacteria are related to cough sensitivity and pneumonia in a clinical stroke population.

Effect of a Novel Transition Program on Disability After Stroke: A Trial Protocol.

A gap in care for stroke survivors exists at the point of transition from inpatient rehabilitation to home, when survivors encounter new environmental barriers because of the cognitive and sensorimoto...

An assessor-participant blinded, randomized controlled trial of dense cranial electroacupuncture stimulation plus body acupuncture for neuropsychiatric sequelae of stroke.

Acupuncture has benefits in the rehabilitation of neuropsychiatric sequelae of stroke. This study was aimed to evaluate the effectiveness of dense cranial electroacupuncture stimulation plus body acup...

Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with hematologic malignancy: therapeutic drug monitoring, efficacy, and risk factors for the suboptimal level.

Posaconazole is used to prevent invasive fungal infections (IFIs) in patients with hematologic malignancy. In this study, we compared plasma posaconazole concentrations (PPCs) and the incidence of bre...

Medical and Biotech [MESH] Definitions

Restoration of functions to the maximum degree possible in a person or persons suffering from a stroke.

Stroke caused by lacunar infarction or other small vessel diseases of the brain. It features hemiparesis (see PARESIS), hemisensory, or hemisensory motor loss.

A branch of dentistry dealing with diseases of the oral and paraoral structures and the oral management of systemic diseases. (Hall, What is Oral Medicine, Anyway? Clinical Update: National Naval Dental Center, March 1991, p7-8)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)

More From BioPortfolio on "Study Evaluating Efficacy and Safety of OSU6162 in the Treatment of Residual Symptoms After Stroke"

Quick Search

Relevant Topics

Stroke - Cerebrovascular Disease (CVA)
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. Strokes are a medical emergency and prompt treatment is essential because the sooner a person receives treatment for a stroke, the less damage is ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial